The Yale spinout has closed an oversubscribed $80m funding round that featured Osage University Partners and Connecticut Innovations, boosting its total funding to $100m.
Biohaven Pharmaceutical, a biopharmaceutical spinout of Yale University, yesterday closed an $80m series A round from investors that included spinout-focused investment firm Osage University Partners.
The round was led by Venrock and further included state-backed Connecticut Innovations, Vivo Capital, RA Capital Management, Aisling Capital, Rock Springs Capital, Knoll Capital Management, Aperture Venture Partners and Litmore Capital, as well as angel investors John Childs and Greg Bailey.
The spinout previously achieved a first close at $40m in November 2016 from the…
